Eli Lilly and Company (LLY) Stock Analysis
Latest ClaritX AI analysis ·
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for n
| Metric | Value |
|---|---|
| Price | $1157.49 |
| Market cap | $1.09T |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| ClaritX AI score | 94/100 |
| Price/Book | 30.49 |
| Dividend yield | 0.58% |
| Beta | 0.45 |
AI verdict
Eli Lilly (LLY) represents an apex, highly de-risked accumulation opportunity within the global mega-cap equity universe, fortified by flawless fundamentals and an elite technical framework. Currently priced at $1,157.49, the stock is positioned exactly 10.45% below its absolute 52-week high of $1,292.65. Acquiring a $1.09 trillion pharmaceutical monopoly—operating with an impenetrable 83.40% gross margin and an astonishing 92.58% ROE—at a 10.45% discount to its euphoric peak provides a mathematically superior margin of safety compared to chasing blow-off tops. This strategic entry is heavily insulated by LLY's deeply defensive beta of 0.454, effectively shielding the equity from broader macroeconomic volatility and abrupt sector rotations while preserving immense upside optionality. Fundamentally, the company operates with a heavily compressed trailing PEG ratio of 0.409, definitively proving the stock is structurally undervalued relative to its explosive forward earnings velocity. The stock has successfully recaptured its 20-day SMA, indicating a resumption of short-term institutional demand as the RSI climbs constructively to 56.93. Backed by a historic evaporation of insider selling, a flawlessly executed 21.65% dividend payout ratio, and upcoming earnings estimates anticipating a staggering $22.31 billion in quarterly revenue, Eli Lilly presents an unassailable long-term growth thesis heading into late October. Rating 94/100
What this score has been worth
ClaritX scores LLY 94 out of 100 (snapshot 2026-10-15).
Every ClaritX analysis is scored first and judged only on what the stock did afterwards. Across the 57 analyses that scored in the 90-100 band, the average forward return was -0.4% with a 44% win rate, -5.3pp against the S&P 500. That is a measured tendency across many names, not a forecast for LLY — roughly 56% of stocks in this band still lost money.
The full band-by-band table, including the bands that lost, is on the AI Rank Report; the live strategy arms behind it are on the AI Track Record, losses published.